Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focusing on obesity and Type 2 Diabetes treatments, has scheduled its third quarter 2024 financial results announcement and business updates for November 12, 2024, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focusing on obesity and Type 2 Diabetes treatments, has scheduled its third quarter 2024 financial results announcement and business updates for November 12, 2024, at 4:30 p.m. ET. The company will host a live webcast accessible through their investor relations website, with a replay option available after the event.
Details
News Market Reaction – GUTS
The recorded move for GUTS in the trading session of this news was +23.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will report financial results for the third quarter 2024 and provide business updates on Tuesday, November 12, 2024, at 4:30 p.m. ET.
A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com. 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com. 978.760.5622
Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com. 619.949.3681
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.